# Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients

> **NCT05275491** · — · COMPLETED · sponsor: **Aswan University Hospital** · enrollment: 66 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** Calcium
- **DIAGNOSTIC_TEST:** Fibroblast growth factor 23
- **DIAGNOSTIC_TEST:** Sclerostin
- **DIAGNOSTIC_TEST:** parathyroid hormone

## Key facts

- **NCT ID:** NCT05275491
- **Lead sponsor:** Aswan University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275491, "Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05275491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*